Literature DB >> 20139821

Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas.

Madhavi Tripathi1, Rajnish Sharma, Maria D'Souza, Abhinav Jaimini, Puja Panwar, Raunak Varshney, Anupama Datta, Nitin Kumar, Gunjan Garg, Dinesh Singh, Rajesh K Grover, Anil K Mishra, Anupam Mondal.   

Abstract

INTRODUCTION: We undertook this prospective study to compare amino acid metabolism, glucose metabolism, and proliferation in primary and recurrent low grade gliomas using positron emission tomography (PET)/computed tomography with F-18 FDOPA, F-18 FDG, and F-18 FLT.
METHODS: Fifteen patients with newly diagnosed or previously treated low grade gliomas (WHO grade I or II) were subjected to F-18-FDOPA, F-18 FDG, and F-18 FLT PET/computed tomography studies on consecutive days. This included 2 patients in remission as control subjects. Uptake of all the 3 tracers were analyzed visually and quantified using standardized uptake values and tumor to normal (T/N) ratios. The accuracy of all the 3 PET tracers in the detection of newly diagnosed and recurrent low grade gliomas was compared.
RESULTS: F-18 FDOPA was positive in all cases of primary and recurrent low grade gliomas and negative in the patients in remission. Tumor was visualized on F-18 FDG in 7 of 13 cases, F-18-FLT was positive in 4 of 13 cases. Average tumor standardized uptake values max for F-18 FDOPA (5.75 +/- 4.9) and F-18 FLT (1.8 +/- 0.91) was lower than that of F-18 FDG (8.5 +/- 4.4). T/N ratios for F-18-FDOPA (2.3 +/- 0.51) and F-18 FLT (1.8 +/- 0.91) were higher than F-18 FDG (1.03 +/- 0.64) providing good image contrast for tumor detection in positive cases.
CONCLUSION: F-18 FDOPA scan is superior to both F-18 FLT and F-18 FDG for visualization of primary and recurrent low grade gliomas. F-18-FLT should not be considered for evaluation of recurrent low grade gliomas.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20139821     DOI: 10.1097/RLU.0b013e3181becfe0

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  30 in total

1.  Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy.

Authors:  Johannes Schwarzenberg; Johannes Czernin; Timothy F Cloughesy; Benjamin M Ellingson; Whitney B Pope; Tristan Grogan; David Elashoff; Cheri Geist; Daniel H S Silverman; Michael E Phelps; Wei Chen
Journal:  Clin Cancer Res       Date:  2014-03-31       Impact factor: 12.531

Review 2.  Metabolic positron emission tomography imaging in cancer detection and therapy response.

Authors:  Aizhi Zhu; Daniel Lee; Hyunsuk Shim
Journal:  Semin Oncol       Date:  2011-02       Impact factor: 4.929

Review 3.  Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.

Authors:  Nathalie L Albert; Michael Weller; Bogdana Suchorska; Norbert Galldiks; Riccardo Soffietti; Michelle M Kim; Christian la Fougère; Whitney Pope; Ian Law; Javier Arbizu; Marc C Chamberlain; Michael Vogelbaum; Ben M Ellingson; Joerg C Tonn
Journal:  Neuro Oncol       Date:  2016-04-21       Impact factor: 12.300

4.  Synthesis, Radiolabeling, and Biological Evaluation of (R)- and (S)-2-Amino-5-[(18)F]fluoro-2-methylpentanoic Acid ((R)-, (S)-[(18)F]FAMPe) as Potential Positron Emission Tomography Tracers for Brain Tumors.

Authors:  Ahlem Bouhlel; Dong Zhou; Aixiao Li; Liya Yuan; Keith M Rich; Jonathan McConathy
Journal:  J Med Chem       Date:  2015-05-04       Impact factor: 7.446

Review 5.  Brain tumors.

Authors:  Karl Herholz; Karl-Josef Langen; Christiaan Schiepers; James M Mountz
Journal:  Semin Nucl Med       Date:  2012-11       Impact factor: 4.446

Review 6.  Molecular imaging of brain tumors with radiolabeled choline PET.

Authors:  Ferdinando Franco Calabria; Manlio Barbarisi; Vincenzo Gangemi; Giovanni Grillea; Giuseppe Lucio Cascini
Journal:  Neurosurg Rev       Date:  2016-05-26       Impact factor: 3.042

7.  18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study.

Authors:  Chirag B Patel; Elisa Fazzari; Ararat Chakhoyan; Jingwen Yao; Catalina Raymond; Huytram Nguyen; Jasmine Manoukian; Nhung Nguyen; Whitney Pope; Timothy F Cloughesy; Phioanh L Nghiemphu; Johannes Czernin; Albert Lai; Benjamin M Ellingson
Journal:  J Neurooncol       Date:  2018-04-20       Impact factor: 4.130

8.  Evaluation of 3'-deoxy-3'-[18F]-fluorothymidine (18F-FLT) kinetics correlated with thymidine kinase-1 expression and cell proliferation in newly diagnosed gliomas.

Authors:  Aya Shinomiya; Nobuyuki Kawai; Masaki Okada; Keisuke Miyake; Takehiro Nakamura; Yoshio Kushida; Reiji Haba; Nobuyuki Kudomi; Yuka Yamamoto; Masaaki Tokuda; Takashi Tamiya
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-15       Impact factor: 9.236

9.  18F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F-FDG PET/CT.

Authors:  Sellam Karunanithi; Punit Sharma; Abhishek Kumar; Bangkim Chandra Khangembam; Guru Pada Bandopadhyaya; Rakesh Kumar; Deepak Kumar Gupta; Arun Malhotra; Chandrasekhar Bal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-03-23       Impact factor: 9.236

10.  Diagnostic and prognostic value of 18F-DOPA PET and 1H-MR spectroscopy in pediatric supratentorial infiltrative gliomas: a comparative study.

Authors:  Giovanni Morana; Arnoldo Piccardo; Matteo Puntoni; Paolo Nozza; Armando Cama; Alessandro Raso; Samantha Mascelli; Michela Massollo; Claudia Milanaccio; Maria Luisa Garrè; Andrea Rossi
Journal:  Neuro Oncol       Date:  2015-09-23       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.